Effect of gemigliptin on glycaemic variability in patients with type 2 diabetes (STABLE study)

STABLE Study Group

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The aim of this study was to evaluate the effect of gemigliptin vs sitagliptin or glimepiride as initial combination therapy with metformin on glycaemic variability and to assess the correlation between glycaemic variability reduction and the dipeptidyl peptidase-4 (DPP-4) inhibition in patients with type 2 diabetes. This multicentre, randomized, active-controlled, open-label exploratory study included 69 patients with HbA1c > 7.5%. Subjects were randomized to receive gemigliptin 50 mg (n = 24), sitagliptin 100 mg (n = 23) or glimepiride 2 mg (n = 22) for 12 weeks. After 12 weeks, the change in mean amplitude of glycaemic excursion (MAGE) compared with baseline was significantly lower in the DPP-4 inhibitor groups compared with that in patients who received glimepiride. Furthermore, the standard deviation (SD) of glucose was significantly lower in patients who received gemigliptin than that in patients who received sitagliptin or glimepiride. The DPP-4 inhibition was significantly correlated with changes in MAGE and SD of glucose. In conclusion, gemigliptin and sitagliptin were more effective than glimepiride in reducing glycaemic variability as initial combination therapy with metformin in patients with type 2 diabetes, and the DPP-4 inhibition was associated with a reduction in glycaemic variability.

Original languageEnglish
Pages (from-to)892-896
Number of pages5
JournalDiabetes, Obesity and Metabolism
Volume19
Issue number6
DOIs
Publication statusPublished - 2017 Jun 1

Fingerprint

glimepiride
Type 2 Diabetes Mellitus
Dipeptidyl Peptidase 4
Metformin
Dipeptidyl-Peptidase IV Inhibitors
Glucose
LC15-0444
Sitagliptin Phosphate

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

@article{4411690f20cd40d2b708c9e648a22a45,
title = "Effect of gemigliptin on glycaemic variability in patients with type 2 diabetes (STABLE study)",
abstract = "The aim of this study was to evaluate the effect of gemigliptin vs sitagliptin or glimepiride as initial combination therapy with metformin on glycaemic variability and to assess the correlation between glycaemic variability reduction and the dipeptidyl peptidase-4 (DPP-4) inhibition in patients with type 2 diabetes. This multicentre, randomized, active-controlled, open-label exploratory study included 69 patients with HbA1c > 7.5{\%}. Subjects were randomized to receive gemigliptin 50 mg (n = 24), sitagliptin 100 mg (n = 23) or glimepiride 2 mg (n = 22) for 12 weeks. After 12 weeks, the change in mean amplitude of glycaemic excursion (MAGE) compared with baseline was significantly lower in the DPP-4 inhibitor groups compared with that in patients who received glimepiride. Furthermore, the standard deviation (SD) of glucose was significantly lower in patients who received gemigliptin than that in patients who received sitagliptin or glimepiride. The DPP-4 inhibition was significantly correlated with changes in MAGE and SD of glucose. In conclusion, gemigliptin and sitagliptin were more effective than glimepiride in reducing glycaemic variability as initial combination therapy with metformin in patients with type 2 diabetes, and the DPP-4 inhibition was associated with a reduction in glycaemic variability.",
author = "{STABLE Study Group} and Park, {Se E.} and byungwan lee and Kim, {Jae H.} and Lee, {Woo J.} and Cho, {Jae H.} and Jung, {Chang H.} and Lee, {Seung H.} and Sunghwan Suh and Hur, {Gwong C.} and Kim, {Sung H.} and Jang, {Young H.} and Park, {Cheol Y.}",
year = "2017",
month = "6",
day = "1",
doi = "10.1111/dom.12869",
language = "English",
volume = "19",
pages = "892--896",
journal = "Diabetes, Obesity and Metabolism",
issn = "1462-8902",
publisher = "Wiley-Blackwell",
number = "6",

}

Effect of gemigliptin on glycaemic variability in patients with type 2 diabetes (STABLE study). / STABLE Study Group.

In: Diabetes, Obesity and Metabolism, Vol. 19, No. 6, 01.06.2017, p. 892-896.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effect of gemigliptin on glycaemic variability in patients with type 2 diabetes (STABLE study)

AU - STABLE Study Group

AU - Park, Se E.

AU - lee, byungwan

AU - Kim, Jae H.

AU - Lee, Woo J.

AU - Cho, Jae H.

AU - Jung, Chang H.

AU - Lee, Seung H.

AU - Suh, Sunghwan

AU - Hur, Gwong C.

AU - Kim, Sung H.

AU - Jang, Young H.

AU - Park, Cheol Y.

PY - 2017/6/1

Y1 - 2017/6/1

N2 - The aim of this study was to evaluate the effect of gemigliptin vs sitagliptin or glimepiride as initial combination therapy with metformin on glycaemic variability and to assess the correlation between glycaemic variability reduction and the dipeptidyl peptidase-4 (DPP-4) inhibition in patients with type 2 diabetes. This multicentre, randomized, active-controlled, open-label exploratory study included 69 patients with HbA1c > 7.5%. Subjects were randomized to receive gemigliptin 50 mg (n = 24), sitagliptin 100 mg (n = 23) or glimepiride 2 mg (n = 22) for 12 weeks. After 12 weeks, the change in mean amplitude of glycaemic excursion (MAGE) compared with baseline was significantly lower in the DPP-4 inhibitor groups compared with that in patients who received glimepiride. Furthermore, the standard deviation (SD) of glucose was significantly lower in patients who received gemigliptin than that in patients who received sitagliptin or glimepiride. The DPP-4 inhibition was significantly correlated with changes in MAGE and SD of glucose. In conclusion, gemigliptin and sitagliptin were more effective than glimepiride in reducing glycaemic variability as initial combination therapy with metformin in patients with type 2 diabetes, and the DPP-4 inhibition was associated with a reduction in glycaemic variability.

AB - The aim of this study was to evaluate the effect of gemigliptin vs sitagliptin or glimepiride as initial combination therapy with metformin on glycaemic variability and to assess the correlation between glycaemic variability reduction and the dipeptidyl peptidase-4 (DPP-4) inhibition in patients with type 2 diabetes. This multicentre, randomized, active-controlled, open-label exploratory study included 69 patients with HbA1c > 7.5%. Subjects were randomized to receive gemigliptin 50 mg (n = 24), sitagliptin 100 mg (n = 23) or glimepiride 2 mg (n = 22) for 12 weeks. After 12 weeks, the change in mean amplitude of glycaemic excursion (MAGE) compared with baseline was significantly lower in the DPP-4 inhibitor groups compared with that in patients who received glimepiride. Furthermore, the standard deviation (SD) of glucose was significantly lower in patients who received gemigliptin than that in patients who received sitagliptin or glimepiride. The DPP-4 inhibition was significantly correlated with changes in MAGE and SD of glucose. In conclusion, gemigliptin and sitagliptin were more effective than glimepiride in reducing glycaemic variability as initial combination therapy with metformin in patients with type 2 diabetes, and the DPP-4 inhibition was associated with a reduction in glycaemic variability.

UR - http://www.scopus.com/inward/record.url?scp=85015343732&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015343732&partnerID=8YFLogxK

U2 - 10.1111/dom.12869

DO - 10.1111/dom.12869

M3 - Article

VL - 19

SP - 892

EP - 896

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

SN - 1462-8902

IS - 6

ER -